Modulation of the immune response by deferasirox in myelodysplastic syndrome patients
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F21%3A00013183" target="_blank" >RIV/00023736:_____/21:00013183 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/21:10422841
Result on the web
<a href="https://doi.org/10.3390/ph14010041" target="_blank" >https://doi.org/10.3390/ph14010041</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/ph14010041" target="_blank" >10.3390/ph14010041</a>
Alternative languages
Result language
angličtina
Original language name
Modulation of the immune response by deferasirox in myelodysplastic syndrome patients
Original language description
Deferasirox (DFX) is an oral iron chelator used to reduce iron overload (IO) caused by frequent blood cell transfusions in anemic myelodysplastic syndrome (MDS) patients. To study the molecular mechanisms by which DFX improves outcome in MDS, we analyzed the global gene expression in untreated MDS patients and those who were given DFX treatment. The gene expression profiles of bone marrow CD34+ cells were assessed by whole-genome microarrays. Initially, differentially expressed genes (DEGs) were determined between patients with normal ferritin levels and those with IO to address the effect of excessive iron on cellular pathways. These data indicate DFX modulates the immune response mainly via neutrophil-related genes. Suppression of negative regulators of blood cell differentiation essential for cell maturation and upregulation of heme metabolism observed in DFX-treated patients may contribute to the hematopoietic improvement.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
<a href="/en/project/NV16-31689A" target="_blank" >NV16-31689A: Anti-tumor effects of chelation therapy in myelodysplastic syndrome and identification of new therapeutic biomarkers.</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Pharmaceuticals
ISSN
1424-8247
e-ISSN
—
Volume of the periodical
14
Issue of the periodical within the volume
1
Country of publishing house
CH - SWITZERLAND
Number of pages
14
Pages from-to
"art. no. 41"
UT code for WoS article
000610681000001
EID of the result in the Scopus database
2-s2.0-85099764158